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Abstract
Background: Proteins that are associated with hypertension may be identified by comparing the 2-dimensional
gel electrophoresis (2-DE) profiles of the sera of spontaneously hypertensive rats (SHR) with those generated from
normotensive Spraque-Dawley rats (SDR).
Results: Five proteins of high abundance were found to be significantly altered when the 2-DE serum profiles of
the SHR were compared to those that were similarly generated from the SDR. Analysis by mass spectrometry and
database search identified the proteins as retinol binding protein 4, complement C3, albumin (19.9 kDa fragment),
alpha1 macroglobulin and alpha1 antiproteinase, which are all known to be associated with hypertension. The
altered expression of the two latter proteins was found to be abrogated when similar analysis was performed on
sera of the SHR that were treated with captopril.
Conclusion: Our data suggests that serum alpha1 macroglobulin and alpha1 antiproteinase are potentially useful
complementary biomolecular indicators for monitoring of hypertension.
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Background
Spontaneously hypertensive rats (SHR) have been widely
used as an animal model to investigate primary hyper-
tension and its relationship to cardiovascular diseases.
The SHR strain was generated in the 1960s by Okamoto
et al. by selective breeding of the Wistar-Kyoto rats with
high blood pressure [1]. The blood pressure of SHR
usually rises at around 5-6 weeks of age and the systolic
pressure of an adult SHR may reach a value of between
180 and 200 mmHg. The SHR usually develops charac-
teristics of cardiovascular diseases like hypertrophy of
the heart and blood vessels, which start at around 40
weeks of age [2].
Hypertension has been known to cause the altered
levels of serum or plasma proteins. A considerable num-
ber of proteins have been previously reported to be
altered in levels in the sera of both animals and human
subjects [3-6]. While some of the proteins were thought
to be involved as anti-inflammatory and protective
response [4,7], others were related to endothelial vascu-
lar repair [5], arterial smooth muscle cell growth [6] and
some may instead be the contributing factors of
hypertension.
In the present study, we have investigated the simulta-
neous expression of the high abundant serum proteins
in the normotensive Spraque-Dawley rats (SDR) and
compared it with those expressed in the sera of SHR as
well as the SHR that were treated with captopril.
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Results
Monitoring of rat blood pressure
Table 1 demonstrates the blood pressure of control rats
and those treated with 60 mg/kg body weight/day of
captopril. The blood pressure of the control SDR rat
group showed stable normal systolic pressure. The
hypertensive group of rats (SHR) also showed an
unchanged high level of systolic blood pressure. How-
ever, a significant reduction of the blood pressure was
observed in the captopril-treated SHR.
Profiling of rat serum samples
Figure 1 demonstrates a typical representative 2-DE pro-
tein profile that was generated from a serum sample
obtained from control non-treated SHR. Serum proteins
were separated on the basis of their different pIs and
molecular weights when subjected to 2-DE. Hundreds of
highly-resolved protein spots were detected when the 2-
DE gels were silver-stained. Due to the broad dynamic
range of proteins that are present in the serum, only the
highly abundant proteins were detected by silver stain-
ing. Similar profiles were generated when serum samples
of the SDR and captopril-treated SHR were subjected to
2-DE.
Image analysis of rat serum proteins
When image analysis was performed on the silver-
stained 2-DE gels generated using serum samples
obtained from the SDR and compared to similar profiles
generated from the SHR, the expression of 13 protein
spots was initially found to be significantly altered (p <
0.05). However, only five of the protein spots, i.e. 1, 50,
85, 117, and 211, were truly altered when the p-values
Table 1 Mean systolic blood pressure of control and
captopril-treated rats
Group Systolic blood pressure (mmHg)
Day 1 Day 10
SDR 102 ± 2.0 103 ± 3.4
SHR 197 ± 6.8 196 ± 6.8
C-SHR 191 ± 4.0 151 ± 8.9
SDR - Sprague Dawley rats, SHR - spontaneously hypertensive rats, C-SHR -
captopriltreated SHR. Data are expressed as mean ± S.E.M. Values of p < 0.05
were considered significant.
Figure 1 Image of a representative silver-stained 2-DE gel showing the high abundant proteins detected in an SHR serum. Spots 1, 50,
85, 117 and 211 were significantly altered in levels when image analysis comparing the expression of 2-DE protein spots of SDR serum samples
with those of the SHR. Acid side of the gel is to the left and relative molecular mass declines from the top.
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were corrected for false significant results using the
method of Benjamini and Hochberg [8] (Figure 2).
Using the serum proteins expressed in the sera of nor-
motensive SDR as a standard reference, the levels of two
proteins were found to be significantly lowered (spots 1
and 117) and three proteins (spots 50, 85 and 211) were
apparently enhanced in the sera of the SHR. However,
only spots 1, 50 and 85 maintained to be significantly
altered in levels when the serum 2-DE profiles of SHR
that were treated with captopril were compared those of
Figure 2 Relative expression of protein spots of interest in sera of SDR, SHR and captopril-treated SHR. The percentage of volume
contribution was determined using the Image Master 2D Platinum Software 7.0. Relative volumes of spots 1, 50, 85, 117 and 211 were
significantly different when comparison was made between SHR and SDR. However, only spots 1, 50 and 85 were significantly different when
the 2-DE images of captopriltreated SHR were compared to those obtained from SDR. Y axis of histogram indicates percentage of volume
contribution. Asterisks denote significantly different values relative to the SDR (p< 0.00233).
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the normotensive SDR (Figure 2). The expression of
spots 117 and 211 was apparently no longer significantly
different and appeared to be normalised. Cropped
images of the five serum protein spots in 2-DE gels of
control and experimental rats are shown in Figure 3.
Identification of differentially-expressed rat serum
proteins
The five differentially expressed protein spots were con-
fidently identified by mass spectrometry using the 4800
Plus MALDI TOF/TOF analyzer and MASCOT data-
base search (Table 2). They were retinol binding protein
4 (RBP4; spot 1), complement C3 (C3; spot 85), albumin
(ALB; spot 50), alpha1 macroglobulin (A1MG; spot 117)
and alpha 1 antiproteinase (A1AP; spot 211). The albu-
min spot was apparently resolved in the region of
around 19.9 kDa in the 2-DE serum protein profiles,
suggesting that it was a fragment of the protein (ALBf).
Discussion
In the present study, we firstly demonstrated a signifi-
cant hypotensive effect of captopril following a 10-day
treatment. This acute duration treatment showed a 20%
hypotensive response, whereby the baseline blood pres-
sure of 191 mmHg was reduced to 151 mmHg (Table
1). When the sera of SHR were subjected to 2-DE and
compared to similar profiles generated from those of
SDR, the levels of five protein spots were found to be
significantly altered. The spots were subsequently identi-
fied as those of the RBP4, C3, a 19.9 kDa fragment of
ALB, A1MG and A1AT (Table 2). All proteins have
been previously identified to have some association with
hypertension. The levels the proteins were earlier
reported to be altered in the SHR as well as patients
with hypertension, although the experiments were car-
ried out on individual proteins. In this study, the differ-
ent altered levels of the five serum proteins were
detected simultaneously using the gel-based proteomics
approach. Interestingly, the altered expression of A1MG
and A1AT appeared to be abrogated in the SHR that
were treated with captopril as their serum levels were
no longer significantly different from those of the SDR.
RBP4 is responsible of delivering retinol to tissues [9].
Many studies have associated the serum/plasma protein
with insulin resistance and diabetic complications
[10,11]. RBP4 was reported to be elevated in patients
with pregnancy-induced hypertension, possibly as a
result of perturbed maternal glucose metabolism [12],
and in women with hypertension caused by insulin
resistance [13]. In contrast to these reports, our results
demonstrated a significant reduction of RBP4 in both
the non-treated and captopril-treated SHR groups.
Treatment of the SHR with captopril did not appear to
induce a significant change in the reduced serum levels
of RBP4.
C3 is a complement component involved in both the
humoral and innate immunity. The levels of C3 were
found to be altered in the sera of patients with idio-
pathic pulmonary arterial hypertension [14], although
the nature of this association is unclear. Studies per-
formed by Lin et al. correlated the differential expres-
sion of C3 with the enhanced growth of arterial smooth
muscle cells from SHR, prior to the development of
hypertension [6]. C3 apparently mediates the arterial
smooth muscle cell growth in the rats. The data of our
study further confirms the altered levels of C3 in SHR.
Like RBP4, however, the levels of C3 in the sera of SHR
that were treated with captopril remains significantly
different from that expressed in the SDR.
Serum ALB levels have been previously associated
with hypertension. In an epidemiological investigation,
increasing albumin concentration in the serum within
the physiological range was found to correlate with the
increase in systolic and diastolic blood pressure in men
and women in all age groups [15]. However, the albu-
min spot that was significantly enhanced in both non-
treated and captopril-treated SHR compared to SDR in
our study appeared to be a 19.9 kDa fragment of the
serum protein. These fragments may be a result of the
proteolysis of serum albumin, although currently no
Figure 3 Representative cropped images of selective protein
spots of interest in rat serum. Panels A, B and C refer to the
protein spots detected in the sera of SDR, SHR and Captopril
treated SHR (C-SHR), respectively.
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information is available on the association of serum
albumin with hypertension in rats.
A1MG, which is identical to the a2-macroglobulin
that is present on the vascular endothelial cells in
humans, binds to a group of serine proteases called
tonins in rat tissues [16]. Tonin acts on angiotensin I
(Ang I), as well as angiotensinogen (AG) and other pep-
tides presenting the N-terminal sequence of AG to form
the vasoconstrictor peptide, angiotensin II (Ang II). The
tonin-a1-macroglobulin complex can generate Ang II
from Ang I despite complete inhibition of the Ang I
converting enzyme [17]. Studies have demonstrated the
capability of tonin to release bradykinin directly, thus
suggesting that the protease is involved in the kininten-
sin system that generates both the pressor (AngII) and
depressor (bradykinin) [18]. When taken together, these
findings suggest that A1MG may play a role in the regu-
lation of blood pressure. In the present study, the low
levels of A1MG detected in the SHR compared to SDR
provide some explanation for the increase in blood pres-
sure in the SHR. The lowered levels were apparently
normalised when the SHR were treated with captopril,
which indicates an inverse correlation of the serum
A1MG levels with hypertension.
A1AT is a serine protease inhibitor (serpin) that func-
tions as an antitrypsin as well as an antithrombin [19].
Its primary target includes elastase, plasmin and throm-
bin. A1AT protects the connective tissues (elastin) from
inflammatory enzymes such as elastase in the lungs and
pulmonary system, as well as helps to prevent blood
coagulation. Levels of the serum acute-phase protein
were shown to correlate positively with blood pressure
in humans [4].
Similarly, our results indicated that the levels of A1AT
were increased in the sera of SHR compared to SDR,
suggesting an acute-phase response to the increase of
blood pressure in the SHR. Treatment of the SHR with
captopril appeared to demonstrate an apparent abroga-
tion of the altered levels of A1AT in sera of the rats,
which further suggests a direct correlation of A1AT
levels with hypertension.
Conclusion
Taken together, our data appear to indicate that hyper-
tension causes the different altered expression of RBP4,
C3, ALBf, A1MG and A1AT in the rat serum and that
the altered levels of the two latter proteins were appar-
ently normalized when the rats were treated with capto-
pril. Unlike the previous results of others that showed
similar altered levels of proteins individually, our proteo-
mics analysis was able to demonstrate the altered levels
of the proteins simultaneously in the rat serum samples.
Together, these proteins have the potential to be used
as indicators for monitoring of hypertension and its
adverse consequences.
Materials and methods
Rat
SHR and SDR aged between 8-10 weeks (weighing 250-
320 g) were used throughout the study. In this study,
the SDR was used as control normotensive rats as they
are less prone to hypertension compared to the WKY.
All rats were singly caged and housed under environ-
mentally controlled conditions with 12 hours of light
and dark cycles and free access to pellet and water ad
libidum at the Animal House, Faculty of Medicine, Uni-
versity of Malaya. All treatments were performed
according to the standard recommended procedure
described in the Helsinki declaration.
Treatment with captopril
Captopril was solubilised in distilled water (60 mg/kg
body weight) and provided to a group of SHR (n = 6)
daily for 10 consecutive days in the form of drinking
solution (30 ml per rat/day). Untreated SHR (n = 6) and
SDR (n = 6) received tap water for drinking. Captopril
treated rats will only received normal tap water once
the 30 ml dosage has been fully consumed.
Monitoring of indirect blood pressure
Baseline blood pressure was measured on the first (day
1) and further monitored on the last day of treatment
(day 10). Systolic blood pressure was assessed on
Table 2 Mass spectrometric identification of differentially expressed rat serum proteins
Spot
ID
Matched protein
identity
Accession number (Swiss-
Prot)
Theoretical mass
(Da)
Theoretical
pI
MASCOT
score
No. of peptides
matched
1 RBP4 P04916 23 205 5.69 596 8
50 ALB P02770 68 686 6.09 82 10
85 C3 P01026 186 342 6.12 200 5
117 A1MG P01023 167 019 6.46 547 8
211 A1AT P17475 46 107 5.70 609 9
Spot ID are as in Figure 1. RBP4, ALB, C3, A1MG and A1AT refer to retinol binding protein 4, albumin, complement C3, alpha1 macroglobulin and alpha1
antiproteinase, respectively. Accession numbers are from the MASCOT database (http://www.matrixscience.com).
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preheated conscious rat by tail-cuff method using a non-
invasive blood pressure controller coupled to a Powerlab
system (AD Instuments Pty Ltd, NSW, Australia). Blood
samples were drawn from the rats on the 11th day and
sera were obtained by centrifugation of the blood at 4°C.
Serum samples were stored in aliquots at -20°C, prior to
the experiments.
Two-dimensional electrophoresis
Two-dimensional electrophoresis (2-DE) was performed
as previously described [20]. Serum samples, each con-
taining 100 mg of protein (estimated using BCA™ Pro-
tein Assay Kit), were mixed with 450 μl rehydration
solution containing 8 M urea, 2% w/v CHAPS, 0.5% v/v
IPG buffer, 0.002% w/v bromophenol blue and 10% w/v
DTT for 30 min at room temperature. The mixtures
were then centrifuged at 1000 rpm for 5 min. The sam-
ples were subjected to isoelectric focusing in 24 cm
rehydrated precast Immobilline Drystrips at pH 4-7 (GE
Healthcare Biosciences, Uppsala, Sweden). For the sec-
ond dimension, focused samples in the strips were sub-
jected to electrophoresis using 11% polyacrylamide gel
in presence of SDS.
Staining of 2-DE gels
Gels were silver-stained using the protocol described by
Heukeshoven and Dernick [21]. A modified silver stain-
ing approach was used for gels analysed by mass spec-
trometry [22].
Image analysis
Silver-stained gels were scanned using the ImageScanner
III. Analysis of serum protein spot volume was per-
formed using the ImageMaster Platinum 7.0 software
(GE Healthcare Biosciences, Uppsala, Sweden). Percen-
tage of spot volume contribution refers to the spot
volume of a protein expressed as a percentage of the
total spot volume of all detected proteins. Results
obtained from proteins that were expressed in sera of
SDR were used as standard references for comparative
purposes.
Sample preparation for mass spectrometry
Samples were prepared as previously described [23].
Protein spots were manually excised from gels and kept
in clean microfuge tubes containing small volumes of
Milli-Q water to keep them hydrated. The gel plugs
were destained using 15 mM potassium ferricyanide in
50 mM sodium thiosulphate and further reduced and
alkylated using 10 mM dithiothreitol and 55 mM iodoa-
cetamide in 100 mM ammonium bicarbonate, respec-
tively. Following thorough washings with 50%
acetonitrile (ACN) in 100 mM ammonium bicarbonate
and 100% ACN, the gel plugs were dehydrated using
vacuum centrifugation. The dried plugs were then incu-
bated in 30 μl of 7 ng/μl trypsin in 40 mM ammonium
bicarbonate in 10% ACN solution at 37°C overnight.
Peptides were finally extracted using 50% and 100%
ACN and subsequently dried using a vacuum centrifuge.
Mass spectrometry
Dried peptides were reconstituted with 0.1% formic acid
and desalted using ZipTip C18 (Millipore, Billerica,
USA) according to the protocol described by the manu-
facturer. The final elution volume following ZipTip
cleanup was then mixed with an equal volume of matrix
consisting of a saturated solution of a-cyano-4-hydroxy-
cinnamic acid (Sigma Chemical Co., St. Louis, USA)
prepared in 50% ACN/0.1% TFA. Each sample was
immediately spotted (0.7 μl) onto a stainless-steel sam-
ple target plate. The samples were analyzed using the
4800 Plus MALDI TOF/TOF analyzer (Applied Biosys-
tem/MDS Sciex, Toronto, Canada), with the mass stan-
dard kit serving as the calibrator for the resulting MS
and MS/MS mass spectra scales.
Protein identification
Data obtained from the MS/MS analysis was generated
using peaklist software 4000 Series Explorer (release ver-
sion 3). The data was exported for search using the
MASCOT search engine (Matrix Science, London, UK;
release version 2.2) against Rodentia entries in the NCBI
non-redundant database. Database parameters used
were: enzyme/trypsin; one missed cleavage allowed;
fixed modification/carbamidomethyl (cysteine); variable
modification/oxidation (methionine); mass tolerance for
precursor ion/peptide tolerance: 50 ppm and mass toler-
ance for fragment ion/MS/MS tolerance: 0.1 Da. The
cut-off score for accepting individual MS/MS spectra
was set at .29 for homology and .38 for matched
identity.
Statistical analysis
ANOVA was used to analyze the significance of differ-
ences between SDR, captopril-treated and non-treated
SHR. All values are presented as mean ± S.E.M (stan-
dard error of the mean). The false discovery rate control
was performed using the method of Benjamini and
Hochberg [8]. After correction, p values of less than
0.00233 were considered significant.
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